43 related articles for article (PubMed ID: 38725010)
1. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia.
Becker PS; Kantarjian HM; Appelbaum FR; Petersdorf SH; Storer B; Pierce S; Shan J; Hendrie PC; Pagel JM; Shustov AR; Stirewalt DL; Faderl S; Harrington E; Estey EH
Br J Haematol; 2011 Oct; 155(2):182-9. PubMed ID: 21848522
[TBL] [Abstract][Full Text] [Related]
2. Limited Efficacy of Venetoclax Combination Regimens in Acute Myeloid Leukemia with Extramedullary Relapse.
Bae S; Sa S; Park S; Cho BS; Kim HJ
Acta Haematol; 2024; 147(3):352-359. PubMed ID: 37751714
[TBL] [Abstract][Full Text] [Related]
3. A hybrid protocol CLAG-M, a possible player for the first-line therapy of patients with mixed phenotype acute leukemia. A Polish Adult Leukemia Group experience.
Karasek M; Armatys A; Skarupski M; Bołkun Ł; Budziszewska K; Drozd-Sokołowska J; Zarzycka E; Mensah-Glanowska P; Gajewska M; Hałka J; Kopacz A; Prejzer W; Chyrko O; Wróbel T; Wierzbowska A; Sobas M
Front Oncol; 2024; 14():1395992. PubMed ID: 38835383
[TBL] [Abstract][Full Text] [Related]
4. Erythroid Predominance in Bone Marrow Biopsies of Acute Myeloid Leukemia Patients after Decitabine Treatment Correlates with Mutation Profile and Complete Remission.
Tiso F; Hebeda KM; Langemeijer SMC; de Graaf AO; Martens JHA; Koorenhof-Scheele TN; Knops R; Kroeze LI; van der Reijden BA; Jansen JH
Pathobiology; 2024 Apr; ():1-12. PubMed ID: 38643752
[TBL] [Abstract][Full Text] [Related]
5. Decitabine as epigenetic priming with CLAG induce improved outcome of relapsed or refractory acute myeloid leukemia in children.
Zhang N; Li H; Wang D; Wang Z; Zhu JS; Chen K; Jiang H; Shao JB; Cai C
Clin Epigenetics; 2024 May; 16(1):63. PubMed ID: 38725010
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia.
Yao H; Zhang C; Tan X; Li J; Yin X; Deng X; Chen T; Rao J; Gao L; Kong P; Zhang X
Cancer Med; 2023 Jun; 12(11):12377-12387. PubMed ID: 37161845
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy.
Tarlock K; Sulis ML; Chewning JH; Pollard JA; Cooper T; Gamis A; Shenoy S; Kutny M; Horan J; Meshinchi S; Boelens JJ; Bleakley M; Carpenter PA; Kolb EA
Transplant Cell Ther; 2022 Sep; 28(9):530-545. PubMed ID: 35717004
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Kadia TM; Ravandi F; Borthakur G; Konopleva M; DiNardo CD; Daver N; Pemmaraju N; Kanagal-Shamanna R; Wang X; Huang X; Pierce S; Rausch C; Burger J; Ferrajoli A; Jain N; Popat U; Estrov Z; Verstovsek S; Jabbour E; Garcia-Manero G; Kantarjian H
Am J Hematol; 2021 Aug; 96(8):914-924. PubMed ID: 33901324
[TBL] [Abstract][Full Text] [Related]
9. Reinduction chemotherapy regimen involved decitabine and cladribine improves the prognosis of patients with relapsed or refractory acute myeloid leukemia: A preliminary study.
Hui Y; Li Y; Tong X; Huang L; Mao X; Huang L; Zhang D
Int J Cancer; 2021 Apr; ():. PubMed ID: 33837553
[TBL] [Abstract][Full Text] [Related]
10. Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re-induction chemotherapy.
Ruan M; Liu LP; Zhang AL; Quan Qi B; Liu F; Liu TF; Liu XM; Chen XJ; Yang WY; Guo Y; Zhang L; Zou Y; Chen YM; Zhu XF
Cancer Med; 2021 Feb; 10(3):956-964. PubMed ID: 33491298
[TBL] [Abstract][Full Text] [Related]
11. Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study.
Wang H; Wang L; Li C; Wuxiao Z; Shao R; Wang H; Lu Y
Oncologist; 2020 Nov; 25(11):e1663-e1670. PubMed ID: 32845551
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm.
Palmieri R; Buckley SA; Othus M; Halpern AB; Percival MM; Scott BL; Hendrie PC; Becker PS; Oehler VG; Estey EH; Walter RB
Leuk Lymphoma; 2020 Jul; 61(7):1728-1731. PubMed ID: 32077361
[No Abstract] [Full Text] [Related]
13. Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo Clinic Cancer Center: Analysis of survival after 'CLAG-M' vs. 'MEC'.
Scheckel CJ; Meyer M; Betcher JA; Al-Kali A; Foran J; Palmer J
Leuk Res; 2020 Mar; 90():106300. PubMed ID: 32018118
[TBL] [Abstract][Full Text] [Related]
14. Re-induction with modified CLAG regimen in relapsed or refractory acute myeloid leukemia in children bridging to allogeneic hematopoietic stem cell transplantation.
Zhang N; Shao JB; Li H; Yang JW; Chen K; Zhu JS; Jiang H
World J Pediatr; 2020 Apr; 16(2):152-158. PubMed ID: 31748985
[TBL] [Abstract][Full Text] [Related]
15. Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis.
Ma YY; Zhao M; Liu Y; Zhao DF; Wang LX; Chen XP; Li L
Hematology; 2019 Dec; 24(1):507-515. PubMed ID: 31242832
[No Abstract] [Full Text] [Related]
16. The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China.
Wang Y; Chen H; Chen J; Han M; Hu J; Jiong Hu ; Huang H; Lai Y; Liu D; Liu Q; Liu T; Jiang M; Ren H; Song Y; Sun Z; Wang C; Wang J; Wu D; Xu K; Zhang X; Xu L; Liu K; Huang X
Cancer Lett; 2018 Dec; 438():63-75. PubMed ID: 30217562
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.
Gore L; Triche TJ; Farrar JE; Wai D; Legendre C; Gooden GC; Liang WS; Carpten J; Lee D; Alvaro F; Macy ME; Arndt C; Barnette P; Cooper T; Martin L; Narendran A; Pollard J; Meshinchi S; Boklan J; Arceci RJ; Salhia B
Clin Epigenetics; 2017; 9():108. PubMed ID: 29034009
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
Döhner H; Estey E; Grimwade D; Amadori S; Appelbaum FR; Büchner T; Dombret H; Ebert BL; Fenaux P; Larson RA; Levine RL; Lo-Coco F; Naoe T; Niederwieser D; Ossenkoppele GJ; Sanz M; Sierra J; Tallman MS; Tien HF; Wei AH; Löwenberg B; Bloomfield CD
Blood; 2017 Jan; 129(4):424-447. PubMed ID: 27895058
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
